October 4, 2022 7:55am
Will the trend be our friend – can investors continue to rally?
News: Voyager Therapeutics (VYGR +$0.32) announced that Pfizer, Inc. (NYSE: PFE) has exercised its option to license a novel capsid generated from Voyager’s TRACERTM capsid discovery platform to help enable a potential gene therapy program against an undisclosed rare neurologic disease target. Verastem (VSTM +$0.03) recently conducted a second planned interim analysis of the ongoing RAMP 201 trial among patients with recurrent LGSOC. Based on the results, including independently confirmed responses and no new safety signals, the Company is planning to meet with the FDA) in Q4 to review the data set, discuss the go forward treatment regimen selection and align on a regulatory path forward.
Indications: 1 Negative Indications, 2 BUYs and don’t let Dip, 6 Positive Indication, with 1 Pump/Promote (BSTG – the usual suspect)
No tunnel vision here, this analyst/journalist gets into the weeds of daily share pricing and root causes
Why do I keep writing this blog/newsletter to inform investors, what they need to hear that others won’t say or write!
8:00 a.m. edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +1.35% or (+399 points), S&P futures are UP +1.65% or (+60 points) and NASDAQ futures are UP +2.07% or (+235 points) early in the pre-open – so far,
Stock futures are jumping on Tuesday,
European markets were also moving up,
Asia-Pacific markets traded higher
Henry’omics:
Monday’s indexes popped after the alternating deep dives in September and Q3. The Dow jumped nearly 2.7%, or 765 points; this was its best day since June 24. The S&P 500 advanced about 2.6% or 92 points in its best day since July 27. The Nasdaq jumped +2.27% or +239.82 points
Economic Data Docket: he Job Openings and Labor Turnover Survey administered by the Bureau of Labor Statistics.
RegMed Investors’ (RMi) closing bell: “snap, crackle and a pop as cell and gene therapy sector closes positive on first session of October” … https://www.regmedinvestors.com/articles/12632
Ebb and flow:
Q4 – 1 positive close
Q3/22 –
· September – 1 holiday, 10 positive and 11 negative closes
· August – 1 neutral, 11 positive and 11 negative closes
· July - 1 holiday, 10 negative and 10 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Maintain Favorites – BUY and don’t let it dip:
Agenus (AGEN) closed up =$0.04 to $2.09 after Friday’s -$0.01 and Thursday’s -$0.14 with a negative -$0.03 or -1.44% pre-open indication,
Solid Biosciences closed up +$0.0284 to $0.495 after Friday’s -$0.0016 with a positive +$0.01 or +2.57% pre-open indication after merger/acquisition of AvantiBio and a $75 million Bain financing
Positive Indications:
Beam Therapeutics (BEAM) closed up =$0.25 to $47.89 after Friday’s +$0.14, Thursday’s -$3.52, Wednesday’s +$2.61 and last Tuesday’s +$1.85 with a positive +$1.31 or +2.74% pre-open indication,
CRISPR Therapeutics (CRSP) closed down -$2.25 to $63.10 after Friday’s +$0.86, Thursday’s -$2.45, Wednesday’s +$3.31 and last Tuesday’s +$2.53 following the previous Monday’s -$2.05 with a positive +1.70 or +2.69 or -0.68% pre-open indication,
Intellia Therapeutics (NTLA) closed down -$0.13 to $55.83 after Friday’s +$0.67, Thursday’s -$3.35, Wednesday’s +$2.61 and last Tuesday’s +$1.83 following the previous Monday’s +$0.28 with a positive +$2.59 or +4.64% pre-open,
Voyager Therapeutics (VYGR) closed down -$0.29 to $5.63 with a positive +$0.32 or +5.68% pre-open indication on news announced that Pfizer, Inc. (NYSE: PFE) has exercised its option to license a novel capsid generated from Voyager’s TRACERTM capsid discovery platform to help enable a potential gene therapy program against an undisclosed rare neurologic disease target.
uniQure NV (QURE) closed up +$0.77 to $19.53 after Friday’s +$0.84 and Thursday’s -$0.94 with a positive +$0.59 or +3.02% pre-open indication
Verastem (VSTM closed up +$0.02 to $0.87 with a positive +$0.03 or +2.94% on news of recently conducted a second planned interim analysis of the ongoing RAMP 201 trial among patients with recurrent LGSOC. Based on the results, including independently confirmed responses and no new safety signals, the Company is planning to meet with the U.S. FDA in Q4 to review the data set, discuss the go forward treatment regimen selection and align on a regulatory path forward.
Changing Position, Negative Indications:
Caribou Biosciences (CRBU) closed up +$0.05 to $10.60 after Friday’s +$0.13 and Thursday’s -$0.58 with a negative -$0.85 or -8.02% pre-open indication,
Puff/Pump and Promote: Maintaining SELL
Biostage (OTCQB: BSTG) closed down -$0.71 with 2,918 shares traded after Friday’s +$0.10 with2,083 shares traded, Thursday closed FLAT with 1,100 shares traded, Wednesday’s +$1.00 with 1,545 shares traded and last Tuesday’s flat ($0.00) with 2,675 shares traded following the previous Monday’s +$0.39 with 970 shares traded <3-month average = 2,918>,
Questions need to be answered and they NEVER are for shareholders; as the First Amendment of the U.S. Constitution does guarantee the “freedom of speech, or of the press” … but I guess NOT to respond?
- Who, WHAT and WHERE are pumping and promoting the “spikes” in volume and share price … coming from?
- What is DST Capital? Is DST Capital really managed by Mrs. bin Zhao of Weston, Mass and Hong Yu, president of BSTG? Is LIU Dong-hai chairman of D. Phone, one of the largest smartphone retailers in China and Dixintong Technology group; the ultimate funder of DST Capital?
- Are Chinese communist bureaucrats from Beijing, China directing the company’s activities with BSTG being their corporate “concubine”?
The BOTTOM LINE: There is STILL many a concern of sentiment and conviction in the cell and gene therapy sector.
However, I am seeing some blue skies but, sensing some headwinds but, for how long versus Monday’s tailwinds?
The Monday opening was moderate 23 up of 35 (coverage group) however it kept slipping slowly on valuation; closing with an A/D Line (advance/decline) of 19/15 and 1 flat.
I still believe it is a sector “in correction” with the heavy selling in recent weeks. That could mean that investors should remain cautious.
The final Q4 is HERE … and then back to earnings season!
I try to keep it simple … and short as I love my coverage list – yet, the truth will set investors free from electronic and algorithm control!
As I continually write, “The real question that should be asked is how many companies are at the end of sentiments … leash?
Start by looking at cell and gene therapy companies trading below cash!”
When it comes time to invest or even hold onto an investment; I’d say … focus on what percentage ownership of stock … NOT options CEOs and management teams own versus their salary and bonus.
As I have written, “I devote a lot of time to the direction of the sector to reckon the geography of my coverage group.” That doesn't mean you should flee entirely to cash, but investors make sure gains don't evaporate thus … be quick to drop losing positions.
Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
